EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Rare, Yet Targetable: New Perspectives on Ampullary Carcinomas

James Gutmans iD, Alex Friedlaender, Hiba Mechahougui iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27031597 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von James Gutmans und 2 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Department, Geneva University Hospital (HUG), 1205 Geneva, Switzerland. Hauptthemen laut MEDLINE: Ampulla of Vater, Common Bile Duct Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ampullary carcinoma (AC) is a rare gastrointestinal malignancy with dual intestinal and pancreatobiliary differentiation, complicating diagnosis, staging, and treatment. This review synthesizes current epidemiology, pathology, and multi-omic data to outline a pragmatic care pathway: lineage-first at presentation, mutation-fast at progression. Histology remains the primary classifier: the intestinal subtype generally aligns with colorectal regimens, whereas pancreatobiliary and mixed subtypes favor pancreaticobiliary therapy. In selected fit patients, modified FOLFIRINOX may address mixed phenotypes. Next-generation sequencing adds precision by identifying therapeutically relevant alterations, including ERBB2/HER2 amplifications, MSI-high/dMMR, BRAF V600E, and rare NTRK or RET fusions, while KRAS mutations are enriched in pancreatobiliary tumors. We recommend early application of a rapid-core panel (KRAS/BRAF, MSI/dMMR, ERBB2/HER2, RNA-based fusions) to capture high-impact targets, followed by comprehensive profiling at first progression. Liquid biopsy, plasma circulating tumor DNA (ctDNA), or bile-derived DNA may complement tissue and help identify the dominant lineage. Research priorities include ampulla-enriched umbrella trials, explicit AC subcohorts in tissue-agnostic studies, and ctDNA-informed endpoints. This lineage-first, mutation-fast paradigm supports precision care and evidence generation in AC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ampulla of VaterCommon Bile Duct NeoplasmsHumansMutationBiomarkers, Tumor

Stichwörter der Autor:innen

ampullary carcinomaintestinal subtypeliquid biopsynext-generation sequencingpancreatobiliary subtypeprecision oncologyrare cancer

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Oncology Department, Geneva University Hospital (HUG), 1205 Geneva, Switzerland.
  • Clinique Générale Beaulieu, 1206 Geneva, Switzerland.

ORCID-Profile: James Gutmans, Hiba Mechahougui

Zitieren

APA

Gutmans, J., Friedlaender, A., & Mechahougui, H. (2026). Rare, Yet Targetable: New Perspectives on Ampullary Carcinomas. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27031597

Vancouver

Gutmans J, Friedlaender A, Mechahougui H. Rare, Yet Targetable: New Perspectives on Ampullary Carcinomas. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27031597

BibTeX
@article{Gutmans2026,
  author = {Gutmans, James and Friedlaender, Alex and Mechahougui, Hiba},
  title = {Rare, Yet Targetable: New Perspectives on Ampullary Carcinomas},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27031597}
}
Kostenlos starten →